Latest / "Isn't That Interesting?!": Breast Cancer Survivor Stories + Remarkable Research / Season 3 / Episode 8: Dr. Manny Bacolod
Transcript
- 0:00Breast cancer doesn't leave much of A calling card, especially
- 0:03when it comes to finding it in the bloodstream.
- 0:05But scientists aren't backing down in their search.
- 0:09In this episode of Isn't That Interesting, we hear from a
- 0:12Cornell researcher who received a grant from earlier.org to
- 0:16advance that work. Here's our founder and executive
- 0:19director, Martha Kaley. Thank you all for joining us.
- 0:23We've got a very special young man here that we funded and I
- 0:29believe Manny, I think Doctor Manny, I think it was about 2017
- 0:33if I'm. Not yeah, that's.
- 0:35Fine. And this is Doctor Manny Bacalod
- 0:39and but I always call him Doctor Manny and we, we have, he's done
- 0:45the work and I've been watching the work for the LAT.
- 0:49Well, I've been watching the work for 30 years, but he's
- 0:52hardly that old. But anyway, so we're just going
- 0:55to have a chat and let you talk about, let him talk about the
- 0:58grant that we funded for him, particularly startup grant and
- 1:04then and then move forward. But I have to say thank you so
- 1:08very much for participating in this.
- 1:11And he just to give you a little catch up, he's at Cornell and he
- 1:17has been cited in about 2000 different research papers, which
- 1:22I thought was just really recognizable.
- 1:26So I'm going to let you begin with what you do and what you're
- 1:30what the grant was that we funded for you.
- 1:32So, so it's your it's your platform and we're just
- 1:36delighted to have you. Well.
- 1:38Thanks for having me, Martha. You know, it's just a pleasure
- 1:40and honor to be here. And I'm so grateful for that
- 1:44grant that I got back in the 2017.
- 1:49And the, the, the project is, was about developing a test for
- 1:56early detection of breast cancer through by looking at
- 2:02methylation markers, specific methylation markers that's
- 2:07released into the blood by cell free DNA.
- 2:11The cell free DNA or circulating tumor DNA is the one they're,
- 2:16they're the ones released by the cancer cells.
- 2:20And that's why the, the assay that you need to develop it has
- 2:25to be really, really sensitive. Just imagine like a, a pool,
- 2:30like, you know, a swimming pool and then there's like few drops
- 2:34of ink there. And that's what you're trying to
- 2:37detect. That's how that's only like
- 2:39tiny, small amount of molecules. And it's especially challenging
- 2:44in breast cancer. Breast cancer is, you know, the,
- 2:47the, the tumors to begin with, they're not big, you know,
- 2:51especially in the early stage. They don't and they don't have,
- 2:54they don't really shed a lot of this DNA into the blood.
- 2:59That's why the assay that has to be developed, you know, in which
- 3:02we, we tried and we are evolving in that the, the methodology by
- 3:07the way. So back then the assay we
- 3:11developed was it's employed A technique called bisulfide
- 3:15conversion. But the problem with that is it
- 3:19kind of damaged the DNA. And then more recently, we, we
- 3:23developed a, a new method called enzymatic conversion that
- 3:28Apobet, which is actually far better.
- 3:32And then we're also evolving with the technology.
- 3:35So we, we, we came from, you know, a technique called
- 3:39quantitative PCR into digital PCR.
- 3:43And then right now we're, we're, we're trying to use a portable
- 3:48type of sequencing called Oxford Nanoport technology, you know,
- 3:52nanoport sequencing. So, and the, so the, so we, we,
- 3:57we were able to, to publish that paper.
- 4:01And at the same time, we only use at that time, we use only
- 4:04few clinical samples. And then and, and also we, I got
- 4:10involved in a startup company which were, it's called a cure
- 4:15MIC diagnostics, which we are, we, we're, we're, we're, we're
- 4:20trying to translate these technologies into possible
- 4:25diagnostic that can be used in the clinic and as well as
- 4:28commercially. And, but, but what we realized
- 4:31and it not just me, it's a lot of other scientists do, is that
- 4:36breast cancer is far more challenging than say colon or
- 4:43lung because of that nature, that breast cancer does not
- 4:49release a lot of this tumors DNA.
- 4:53It's not just DNA. It can be the other molecules
- 4:56that comes from the tumor because what's kind of happening
- 5:00in liquid biopsy is that it's coming from the blood and
- 5:05there's the the fragments of DNA, for example, that's in the
- 5:12in the blood is mostly from blood cells.
- 5:15So it's only a tiny fraction comes from from tumor.
- 5:19So it's a lot easier. It's a lot easier to do that
- 5:22with colon and lung cancer. Breast cancer is, is, is far
- 5:27more challenging. That's why even the, the, the,
- 5:31the companies that were, you know, far ahead of us in terms
- 5:35of, you know, even raising funds and, and, and then get, get, you
- 5:39know, with the clinical trials, they, they also admit the
- 5:44struggles with breast cancer. But I'm not saying that this
- 5:47hopeless. It is the that's what the reason
- 5:50why, you know, there's a lot of approaches that are being will
- 5:56be tested, are being tested and will be in the future.
- 5:59For example, right now we cannot say that no, we can abandoned
- 6:05mammography, that's not yeah, but that's still very useful.
- 6:09And the, the liquid biopsy tools that are being developed, it's
- 6:14not yet ready, to be honest. Snapchat, you know, they're not
- 6:20yet able to replace it mammography, but there are many
- 6:24opportunities. And, and then the, I would say
- 6:26like, you know, in the next 5 years, there will be the, the,
- 6:30the, a lot more improvement in the, in the technologies.
- 6:34And so the, the past in there could be like combinations of
- 6:38this that we can say that maybe you know, mammography, because
- 6:43mammography the, the, you know, I guess this, this the, the,
- 6:47the, the specificity is, is high enough.
- 6:50You can say that if if the, if the person tested the positive
- 6:56in mammography, then the second molecular test that were liquid
- 7:02biopsy. So it can be complementary.
- 7:06So that's the and, and go ahead. Yes, and and and definitely
- 7:11again, that grant that I got it, it started us to you know, it,
- 7:17it really helped us in developing the technology,
- 7:20although like I said, it became far more advanced in other
- 7:23cancer like colon. The colon is where we, we've
- 7:28gotten more, we were able to analyse more clinical samples
- 7:33and, and, and then we will, we will, it's about to be published
- 7:37the paper. But the those technologies, they
- 7:40can still be applied to, to, to breast cancer.
- 7:44And I I can see that happening. In fact, that's part of our
- 7:47plan. It's just that we, we're still
- 7:49raising funds, you know, for, because that's the thing.
- 7:52So, you know, clinical trials are so expensive, you know, so
- 7:55that's why I so, but there's, there's really hope.
- 7:59I believe so, yeah. I, I just feel like there's,
- 8:03it's, we've progressed exponentially in the last five
- 8:09years that I've been watching it.
- 8:11And I feel like that seeing what you're looking at now.
- 8:16I, I love the fact that you're looking at D, the DNA
- 8:20methylation and the liquid biopsies and biopsy with saliva,
- 8:26with blood, with urine. But also one of the things that
- 8:31I found super interesting to me was the volatile organic
- 8:35compounds because I I firmly believe that my chocolate
- 8:42Labrador was able. He scratched my chest, which led
- 8:47to the discovery of my breast cancer three months after having
- 8:51a clear mantle. So I really felt like that he
- 8:56that this was something that is really emeritus to investigate.
- 9:02And we spoke on an earlier podcast with Doctor Claire Guest
- 9:07and she trains medical sniffing dogs in England.
- 9:12And you know, she had so much to say about the technology of this
- 9:18and how it's changing. And your technology, what you're
- 9:22looking at now is like looking at the interactions of what the
- 9:27tumor is interacting with the regular cells and what the tumor
- 9:32sending out signals that. Can you talk about that for a
- 9:35minute? Well, what happens is that the
- 9:38cancer, what happens in cancer is there's, if you look at it at
- 9:41the DNA level, there's a lot of changes that happen in the DNA.
- 9:45That's why that's what cancer is all about.
- 9:48So the, they're like changes in the, in the, in the, in the, in
- 9:53the cells, mostly on genes that control the division of the
- 9:57cells. So when there is some problem
- 9:59with those either mutation or the, the the expression of of
- 10:03those of those genes gap perturbed, then all of a sudden
- 10:08the the cells are now they don't control the the vision anymore.
- 10:13It divides so fast. That's what that's what cancer
- 10:16is all about. So it can be mutation.
- 10:18That's what happening. So for example, the gene called
- 10:21P53 PIK 3 CA, These are common mutations in in breast cancer.
- 10:27So what, what happens is that this cancer, they, they undergo
- 10:33process called apoptosis. So they, they basically, you
- 10:36know, blow up and then it released fragments of DNA and
- 10:40that gets released into the blood.
- 10:43So the the dose. And then since this came from
- 10:46the cancer cells, so they, they contain the same signatures in
- 10:53the DNA. It can be mutation or
- 10:56methylation. So methylation is it's that
- 11:00that's a term called epigenetics.
- 11:02So when, when we say, you know, when we, when we say genetics is
- 11:06usually the mutation, the, those are the genetic changes, the
- 11:09actual, you know, the base in the DNA would change, but
- 11:13methylation is that. So there's a, there's some
- 11:17changes in, in in a base called cytosine that when they get
- 11:22methylated, they will affect the expression of genes and that
- 11:28also contribute to cancer. So the, you know, that that is,
- 11:32is, is just as important as the mutation, but it in around the
- 11:38well, when people started analyzing the cell free DNA as a
- 11:42surrogate marker for cancer, it is the people first look at
- 11:48mutation. Yes, the end, the end, you know,
- 11:51people thought, oh, that we've solved it, but it turns out
- 11:55there's a lot of limitation on that and also a lot of problem
- 11:58that the, the, the, the hematopoietic ovidic cells are
- 12:04blood. They also contain this mutation
- 12:06they got. So it got confused that's the
- 12:09reason why. And methylation turns out to be
- 12:11a better marker than mutation. So a lot of people in the field
- 12:17have moved to epigenetic tests like methylation and.
- 12:22So my understanding is that the micro RNA is a major component
- 12:29but that is some. So I got a mixed read on whether
- 12:33it is stable or not stable. Well, there are two types of of
- 12:37the like not just spike or any RNA species other they can be
- 12:41released into the blood, you know, cell 3 as well and there
- 12:46or it can be found enclosed in vesicles called yeah, exosomes.
- 12:51So those are a lot of there are many investigators in those
- 12:54field who's studying those those I believe there's a company in
- 12:58in I forgot the name of the company that this is the
- 13:01technologies based on this to detect breast cancer based on
- 13:05the cell free RNA. So either I, I get microarray,
- 13:09these are the smaller pieces of RNA it can be and then the
- 13:11bigger one this they all both of them can be.
- 13:15Again, they also come from the cancer cells.
- 13:18So, and again, it's it, it, it encounters the same problem in,
- 13:23in, in, in terms of breast cancer is because they're just
- 13:26too many, too few of this to begin with in early stage.
- 13:31But but the, so the, the, the, the further the stage, it's
- 13:36easier to detect because there are more cells, more molecules
- 13:40from those cancer will be released into the blood.
- 13:42It's easier to detect them, but but we don't, you know, that's a
- 13:46problem, you know, if we don't do any detection anymore, if
- 13:50it's stage 3 or stage 4, right. So that's the but there are
- 13:54other ladies and Mark that there are many, you know, back there
- 13:58when I got the grant the the use of machine learning, you know,
- 14:01AI, it's not yet widely it's, it wasn't widely used yet.
- 14:07So now we're here. So the, we a lot of people now
- 14:10use this, you know, this predict called predictive modelling that
- 14:14can interpret your results using machine learning to look at
- 14:19those the, you know, this complex relationship with
- 14:22between those data, which I also do and that improves the
- 14:26accuracy of this methods, especially this liquid biopsy.
- 14:32So there, there are many, not just in the, so there are
- 14:35improvements in the technology itself, in the biochemistry.
- 14:39There are also improvements in the analysis and that is
- 14:43actually, you know, you know, so that's the progression.
- 14:47So would you address the the work that you did the last
- 14:53paper. Let's see that I have here
- 14:55you're when you co-authored with Doctor Francis the Ronnie.
- 15:03So and also in in there it was mentioned Doctor Para Julie and
- 15:09Doctor Durante and that they're on the same in the looking at
- 15:13similar things. And we have we've interviewed
- 15:16both of them because we have awarded grants to both of them.
- 15:21But if you would talk to me about that, that that paper with
- 15:25Doctor Borrani, that would be great.
- 15:28Right, sure. So the, the, the, the paper is
- 15:31we started, the first step is to identify those markers, those
- 15:36methylation markers. And we employed and, and, and
- 15:41that's really my, my expertise is to, is the, to analyse this
- 15:46huge datasets that are publicly available.
- 15:50So what, what's really what has been really helpful is back in
- 15:53around, I think early 20 tens, there's a, a project from, from
- 15:58NCI called the Cancer Genome Atlas TCGA.
- 16:03So you're probably familiar with that.
- 16:05So there are like 10,000 samples, different cancers
- 16:09including breast that they molecularly analyse the the look
- 16:14at the expression, they look at methylation, Kappa number and so
- 16:17on and so forth. It is very extensive.
- 16:20And then they made that those public, right?
- 16:23And yeah. And then there are also other
- 16:25databases what they made them public.
- 16:27So the, the methylation data, it, it, it, they came from a
- 16:32technology called Illumina array, methylation array.
- 16:37And so they, they look at the methylation of 450,000 sites in
- 16:41the genome. So, and then we, I analyzed
- 16:44those data, the, those methylation data from, from
- 16:49those 10,000 samples. Then I added another maybe
- 16:5210,000 from other data data sets.
- 16:55So two, yeah, we're talking about billions of that data
- 16:59points that I need to to look at to identify those two.
- 17:04Well, we, we came up with a pool of markers for every cancer,
- 17:07including breast. So these are the one, because
- 17:09what you want is really to identify those markers that is
- 17:13positive in, in breast cancer primary tumors, but as much as
- 17:19possible negative in the normals.
- 17:20So there are normals in those data sets.
- 17:23And also as much as possible it's distinct from from for
- 17:28breast cancer. So it's not as positive in let's
- 17:32say colon or lung or and also not positive in normal blood.
- 17:37So, so we I combine all those data sets.
- 17:40So it's a lot of statistics. Yeah.
- 17:43So it's a bioinformatics very exciting.
- 17:45And then those are the, you know, we apply them to breasts
- 17:48and other cancers. And so we, we, we came up with
- 17:52that list of, I believe we have some like 50 markers of
- 17:56methylation markers and in, in those.
- 17:59And then we, we developed the assay to interrogate them.
- 18:04So the, the method that was used.
- 18:08So it's, it's, it's basically we, we came up with the, it
- 18:14involves A bisulfide conversion. That's the only method.
- 18:17So that will distinguish what's methylated and what is that.
- 18:21And then at the end, if you you will really interrogate that, we
- 18:27measure the output with the method called QPCRPCR and then
- 18:34we look at the profile and then we can say that it's positive or
- 18:38not in those markers. And that that that paper I
- 18:42believe there were only like 3 or 5 methylation markers.
- 18:45Well, yes, I was reading about that and I, I, I just thought
- 18:50to, to be able to narrow it down to, and I, I was impressed, but
- 18:58I'm even more impressed with that because that's just like
- 19:01really trying to find a needle in a haystack, you know?
- 19:04It's just, yeah. And you found that, I mean they
- 19:08found 3 markers and those are so consequential and.
- 19:12Right. Yeah, Well, yeah, so this is the
- 19:15and and then I said, well, we're thankful for that government
- 19:18project and the TCGA, you know, without that that we wouldn't
- 19:22be, you know, identify able to identify those, although those
- 19:25are, you know, taxpayer funded. So, so these are identify those
- 19:29markers and, and you know, the, the natural progression of that
- 19:33is to to look for more clinical samples.
- 19:38That's what initially what our plan is, you know, for, for, for
- 19:41breast cancer as well. It's just that we, you know, we,
- 19:45we were, we, we were, we were not able our company that kill
- 19:48my diagnostic. You know, we're still trying to
- 19:50raise money. And that's that's really what
- 19:52the original plans and, and then and hopefully we will be able
- 19:57to, you know, raise more money and then conduct more, obtain
- 20:02more clinical samples. That's the.
- 20:04And then and then, yeah, so that's the the, the, the
- 20:07challenge right now is that, you know, the first in the US it's
- 20:12so difficult to to find those. You might be surprised to find
- 20:15those clinical samples. Yeah, that is very, that's very.
- 20:19So we actually in, in the, the paper that, you know, we just
- 20:24published, we actually obtained them from commercial sources.
- 20:30The clinical samples. Yeah, yeah.
- 20:33And, and it's, it's so difficult in the US.
- 20:36It's a, it's a, it can be done, but it's, it was challenging.
- 20:39So, you know, so it, it, it's really the results from that
- 20:43paper, you know, it, it prove us, it showed us that this
- 20:48method can be applied to breast cancer.
- 20:52Like I still believe that. I still believe that, but it, it
- 20:56has to be shown, you know, in more clinical samples and, and,
- 21:01and, and hopefully I, I'm hoping that this can be, we were able
- 21:05to continue this, this project in, in breast cancer, because I,
- 21:09I understand the, the, you know, the great need for it and, and,
- 21:16and methylation is really the, it's really the most methylation
- 21:21in blood. I believe it's really the most
- 21:24promising, the more more practical, you know, approach.
- 21:29There's just a lot of promise on that.
- 21:32And yeah, but like I said, there's a lot of challenges.
- 21:37You know, Martha, it says that the, the, the, the breast cancer
- 21:41is really different from other types of cancer because it does
- 21:45not release a lot of this DNA of this cancer related markers into
- 21:49the blood. That's the challenge.
- 21:51But I like, you know, we're continuing to develop the, the
- 21:55technologies. Like I said, we, we moved from
- 21:58technique called by sofa conversion, which damaged the
- 22:01cell free DNA further. And then you can analyze it
- 22:04anymore. We're not developed.
- 22:06We, we, we're now employing a technology called TAP apobank
- 22:11conversion that's enzymatic, which is far better.
- 22:14So I guess it doesn't damage the DNA, the cell free DNA.
- 22:18So it becomes more sensitive and, and there are the, the
- 22:21readouts, you know, come to PCR and then the, the, the digital
- 22:27PCR, you know which you want it to be the technique to be a
- 22:31sensitive as well. You know, the big box sequencing
- 22:34that was, you know, like 10, you know, I would say like 10 years
- 22:38ago it, it became, you know, not as cost effective, but that's
- 22:43the issue, you know, because that's the issue.
- 22:45We also you want the test that can be easily accessible.
- 22:49It's not just, it should be cost effective and there are other
- 22:55technologies that are being developed for this.
- 22:59Yeah, that will be far less expensive.
- 23:01That's the. Well, and I also it's, it's just
- 23:05like you, you open one door, which opens it to three more
- 23:09doors, which opens it to five more.
- 23:11And, and so I just feel like that your work has really opened
- 23:17a lot of information in a, a pathway for finding, finding an
- 23:23issue here that we can that we can work with.
- 23:27Well, I really appreciate your chatting with me.
- 23:31You've done a great job. And I hope that people
- 23:35understand how excited we are about the, the new work and the
- 23:40opportunities that are available.
- 23:42So I thank you so much. It's it's my pleasure.
- 23:46And again, you know, I, I'm so grateful for that grant, you
- 23:49know, it, it really helped, you know, the project that we're
- 23:52doing it and, and, and so hope hopefully in the near future,
- 23:57you know, we will be, you know, able to run more clinical
- 24:01samples for related to breast cancer.
- 24:04And then we'll be celebrating, right?
- 24:06Yeah. Well, thank you for spending
- 24:09time with us. We really appreciate it.
- 24:11And we look forward to, I look forward to chatting with you
- 24:14again sometime. OK, sure.
- 24:15Definitely. Thank you so much.
- 24:18OK, bye, bye. Bye, bye now.
- 24:20This episode of Isn't That Interesting was made possible
- 24:23thanks to volunteers and donors just like you.
- 24:26It was hosted by Martha Kaley, founderofearlier.org and edited
- 24:31by Liam Mcburney. I'm Valerie Amsterdam, reminding
- 24:34you that for the last 30 years, this is North Carolina based
- 24:37organization has helped fund groundbreaking research all over
- 24:41the world, from molecular imaging to a sensitive blood
- 24:45test for breast cancer. Plain and simple, earlier
- 24:48detection saves lives. And you can help host a
- 24:51fundraising event, make a donation or volunteer your time.
- 24:55You can find us not only on the web, but on Facebook and
- 24:58Instagram too. Let's change the picture of
- 25:00breast cancer together.